KYNEXIS Trademark

Trademark Overview


On Tuesday, June 6, 2023, a trademark application was filed for KYNEXIS with the United States Patent and Trademark Office. The USPTO has given the KYNEXIS trademark a serial number of 79374076. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, June 18, 2024. This trademark is owned by KyNexis B.V.. The KYNEXIS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical products, namely, small molecules, biologics and gene therapies, for the treatment of central nervous system diseases and disorders; biological preparations for use in medical and clinical gene therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnostic and gene testing; pharmaceutical preparations for the treatment of central nervous system diseases and disorders, and other pharmaceuticals for the prevention of onset and worsening of central nervous system diseases and disorders

Fundamental product and medical research, product development and consultancy in the field of biotechnology, namely, biomedical research and product development, medical science, chemistry and biochemistry; research and product development in the field of pharmaceuticals
kynexis

General Information


Serial Number79374076
Word MarkKYNEXIS
Filing DateTuesday, June 6, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, June 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 18, 2024

Trademark Statements


Goods and ServicesPharmaceutical products, namely, small molecules, biologics and gene therapies, for the treatment of central nervous system diseases and disorders; biological preparations for use in medical and clinical gene therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnostic and gene testing; pharmaceutical preparations for the treatment of central nervous system diseases and disorders, and other pharmaceuticals for the prevention of onset and worsening of central nervous system diseases and disorders
Goods and ServicesFundamental product and medical research, product development and consultancy in the field of biotechnology, namely, biomedical research and product development, medical science, chemistry and biochemistry; research and product development in the field of pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 14, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, July 14, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKyNexis B.V.
Party Type20 - Owner at Publication
Legal Entity Type26 - NOT AVAILABLE
AddressNL

Party NameKyNexis B.V.
Party Type10 - Original Applicant
Legal Entity Type26 - NOT AVAILABLE
AddressNL

Trademark Events


Event DateEvent Description
Thursday, July 13, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, July 14, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 27, 2024ASSIGNED TO EXAMINER
Tuesday, July 18, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, March 20, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, May 1, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 29, 2024NON-FINAL ACTION WRITTEN
Friday, March 1, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 20, 2024REFUSAL PROCESSED BY MPU
Saturday, April 6, 2024LIMITATION OF GOODS RECEIVED FROM IB
Monday, April 8, 2024REFUSAL PROCESSED BY IB
Wednesday, May 1, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 1, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 2, 2024FINAL REFUSAL E-MAILED
Wednesday, May 15, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, May 15, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, May 15, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 2, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, May 2, 2024FINAL REFUSAL WRITTEN
Wednesday, May 15, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, May 15, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, May 29, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 12, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Thursday, June 13, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, June 14, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, June 18, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 18, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, July 1, 2024NOTIFICATION PROCESSED BY IB
Wednesday, June 5, 2024LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED